The latest international news, analysis and features on the HIV epidemic from Avert. Share your views and expertise with your peers in the comments box below the articles.
Review initially finds dolutegravir has no links to birth defects then revises its findings to report a ‘slightly higher’ – but minimal – incidence after two cases emerge
Long-acting, injectable cabotegravir is as effective as daily PrEP pills at preventing HIV among cisgender men and transgender women who have sex with men.
New research reveals high rates of loss to follow-up among adolescents, with rates among those acquiring the infection in their teens nearly three times that of those infected perinatally.
Long-lasting antiretroviral drugs injected monthly present a ‘remarkable milestone’ in treatment options for people living with HIV
Without urgent action, HIV drug resistance is set to derail the HIV response and presents a significant threat to public health, the World Health Organization (WHO) warns today.
Key HIV drugs added to the list of medicines critical to public health, including tenofovir for HIV prevention, and dolutegravir.
‘Surprising’ research from Conference on Retroviruses and Opportunistic Infections (CROI) shows drug resistance does not impact test-and-treat roll-out in South Africa – at least in the short term.
With 17 million people now accessing antiretroviral treatment worldwide, HIV drug resistance has the potential to unravel progress towards the Fast-Track target of ending AIDS by 2030.
A new pill technology has the potential to simplify HIV treatment and curb the rise of drug-resistant HIV.
